Additional samples from this patient during neoadjuvant chemotherapy and following resection of the primary tumor showed decreasing 5-hmC levels on MYC, consistent with decreased osteosarcoma derived cfDNA from a treated tumor and clinically decreased disease burden (Fig. 4c). This evidence concerns the gene MYC and neoplasm.